The global radiodermatitis market is expected to exhibit high potential over the forthcoming years owing to untapped needs in emerging economies. The rising employment of radiation therapy and growing cases of cancer across the globe. The global radiodermatitis market is also expected to be benefited by the growing focus on research and development projects to develop a standard and appropriate treatment. Players can gain from the opportunity arising from the dearth of standard care products and put into function their innovative ideas for product development and commercial success.
Radiodermatitis is a symptom caused by radiation therapy which is employed in the treatment of cancer and also when exposed to nuclear disasters. During the process of cancer radiotherapy, continuous exposure to radiation weakens the skin site and decreases skin immunity. Radiodermatitis encompasses conditions such as necrosis, fibrosis, hair loss, skin shedding, and localized erythema. It negatively impacts the life quality of a patient and causes discomfort and pain, thus hindering the treatment regimes. Skin specialists and oncologists are the ones who best understand the nuances of patient comfort, effectiveness, product usage. Hence, companies are entering into partnerships with specialist and healthcare units to bridge the gap between patients and specialists and to also capitalize on these opportunities.
The global radiodermatitis market is estimated to witness a 3.9% CAGR between 2016 and 2024 and is likely to touch US$421.5 mn by the end of 2024 from a valuation of US$299.6 mn in 2015.
Topical Segment to Emerge as Dominant Product Type
The global radiodermatitis market was led by the topical segment in 2015 and it is expected that it will retain a lead until 2024. The growth of this segment can be attributed to the affordability and easy off the shelf availability of these products. Tropical agents include topical antibiotics, hydrophilic creams, and corticosteroid creams. As hydrophilic creams provide relief from itching and hydration, they are used extensively across the globe by patients. These are the first purchases of patients suffering from radiation dermatitis.
Based on growth, dressings formed a key segment in the global radiodermatitis market. Compared to topical applicants, these products are priced high. These are a necessary buy for patients who have reached the moist desquamation or RTOG grade 3 stage of radiodermatitis. Positive clinical and academic research regarding benefits associated with dressing such as Mepitel film and Cavilon no-sting barrier film are likely to open a plethora of opportunities for manufacturers.
Browse the full Global Radiodermatitis Market report http://www.mrrse.com/radiodermatitis-market
The Middle East and Africa market to be Driven by Favorable Policies
Geographically, Asia Pacific is likely to emerge dominant in the global radiodermatitis market during the forecast period owing to a large base of cancer patients and rising acceptance of radio therapy across the region. As a large population here is not so well acquainted with hygiene, the number of cancer cases here is more than Europe or North America. However, the MEA is the emerging market for radiodermatitis owing to the implementation of favorable policies by governments.
The key companies in the market are Stratpharma AG, Intermed Pharmaceuticals, Acelity LP, Alliqua Biomedical, Derma Sciences Inc., BMG Pharma, and 3M Health Care.